Group items tagged

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

The Neuroendocrine Tumor Research Foundation (NETRF) is the largest private funder of NET research. Since 2005, NETRF has funded $22 million in scientific research to expand the molecular understanding of NETs and help drive personalized treatment options for patients.  To that end, NETRF has issued a 2019 Request for Applications (RFA) for innovative research that increases our basic understanding of these uncommon tumors and leads to the development of more effective therapies. Grants ranging from $100,000 to $1.2 million will support projects over one to four years in the areas of basic, translational, or clinical research.

The AACR-The Mark Foundation for Cancer Research "Science of the Patient" (SOP) Grants Program represents a joint effort to stimulate novel research aimed at understanding the influence of the biology of the host (i.e., patient) on the genesis, development, treatment, and survivorship of cancer. Successful projects should emphasize the interplay of host physiological systems with the tumor and/or tumor microenvironment. Harnessing the powerful approach of examining cancer not as an isolated phenomenon but as a systemic disease that affects and is affected by both the normal and pathological functions of the patient's body, these grants are expected to yield important advancements in our understanding of cancer development, progression, and treatment. Individuals with innovative ideas that have the potential to affect future clinical practice are particularly encouraged to apply.  Each grant will provide $750,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient and any collaborators, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants; research/laboratory supplies; equipment; travel applicable to the research project; publication charges for manuscripts that pertain directly to the funded project; other research expenses; and indirect costs.

The BTSI is awarded to scientists at the end of their fellowship or in the beginning of their faculty appointment, who are predominantly focused on lab-based, basic/translational research. The BTSI is intended to encourage scientific inquiry in the field of basic/translational science as it relates to NETs. NANETS welcomes applications from candidates who meet the following criteria: - Candidates must have a MD, PhD, MD/PhD, DO degree or equivalent. - At the time of funding, candidates must be in the first 6 years of a faculty appointment at an accredited medical school or other institution in North America. Faculty appointments include instructors and above. - Candidates must be a NANETS member in good standing. - Previous recipients of NBTSI, NCIS or NTIG awards are not eligible to apply. Criteria for selection will include both the research proposal itself and the potential of the individual to make future scientific and/or clinical contributions to the neuroendocrine tumor field. Strong emphasis will be placed on the career development plan and the applicant's personal statements, as well as the research proposal. The research proposals section should focus on research projects with the potential to directly impact and improve the treatment of patients with neuroendocrine tumors.

To that end, the foundation is inviting applications for innovative research with the potential to increase the basic understanding of these uncommon tumors and lead to the development of more effective therapies. Grants ranging between $100,000 to $1.2 million will be awarded in support of projects over one to four years in the areas of basic, translational, or clinical neuroendocrine cancer research. Four different grants will be awarded: Accelerator Award - Grants of up to $1.2 million over four years will be awarded to projects that bring together investigators from diverse scientific disciplines. Investigator Awards - Grants of up to $300,000 over two years will be awarded to investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways. Pilot Awards - Grants of up to $100,000 over one year will be awarded for pilot studies. Mentored Awards - Grants of up to $120,000 over two years will be awarded to encourage early-career investigators to pursue neuroendocrine tumor research and make a commitment to the field.

This Funding Opportunity Announcement (FOA) is a part of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). This reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics and accelerates research in these areas by disseminating research resources for the scientific community. The program will support broad efforts focused on several cancer types to explore further the complexities of cancer proteomes and their connections to abnormalities in cancer genomes.

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).

The Leukemia & Lymphoma Society is accepting Letters of Intent from researchers for projects to identify and develop safer, more effective treatments for patients with blood cancers. Through the Quest for Cures initiative, LLS, in partnership with biopharmaceutical company Celgene, will award two-year grants of between $200,000 and $400,000 a year for research projects that have a measurable impact over the next five to ten years on the diagnosis or treatment of patients with hematologic malignancies. Additional funding may be available for projects that have demonstrated exceptional progress in the initial two years. Specifically, the initiative will award grants in the following priority areas: Tumor cell clonal heterogeneity: This grant will support researchers seeking novel approaches for measuring and monitoring clonal heterogeneity and assessing its contribution to the response or resistance to therapy. New molecular stratification mechanisms: Recipients of this grant will work to identify key subsets of patients with B-cell malignancies to help predict which patients will have poor outcomes from current standard therapies so they may be directed to alternative therapies. Bone marrow and lymph node microenvironments: Researchers will seek to enhance the understanding of the role that the bone marrow and lymph node microenvironments play in either responding to or resisting therapy.

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure, or treatment of primary brain tumors/brain cancer. The annual award provides up to $600,000 in funding over a four-year period. Over that time, recipients also receive additional support from the foundation through its network of scientists in the field and an annual alumni conference.

This Funding Opportunity Announcement (FOA) is a part of the Pediatric Preclinical Testing Consortium (PPTC) initiative. The PPTC will consist of in vivo and in vitro testing Research Programs (both supported under companion RFA-CA-14-018) and the PPTC Coordinating Center (supported under this FOA). The PPTC is designed to address key challenges associated with the development of new therapies for children with cancer by developing reliable preclinical testing data for pediatric drug candidates that can be used to inform new agent prioritization decisions. Effective prioritization is critical because of the large universe of drugs being developed for adult cancers, a number so large that no more than a small number can be studied in pediatric clinical trials. Identifying through preclinical testing those investigational agents most likely to have clinical activity for selected childhood cancers accelerates the pace at which treatments that are more effective than the current ones can be identified and incorporated into standard practice for children with cancer. The PPTC Research Programs, responsible for conducting the in vivo and in vitro testing of selected agents, will be focused on specific tumor types that are particularly relevant to pediatric oncology. The PPTC Coordinating Center, which is subject of this FOA, will be responsible for integrating the activities of the individual PPTC Research Programs to create a functional consortium for pediatric preclinical testing. Specifically, the PPTP-Coordinating Center will provide administrative coordination and infrastructure, data management and statistical support, as well as Consortium scientific coordination.

This funding opportunity announcement (FOA) is a part of cancer genomics programs supported by the National Cancer Institute (NCI) and managed by its Center for Cancer Genomics (CCG). The overall goal of all CCG programs is to help elucidate the mechanisms of cancer initiation and evolution, as well as resistance to therapy by means of genomic characterization of well-annotated, high quality tumor samples.